When there was no beaten path, these pioneers created the path from discovery and technology development, to clinical trial translation, regulatory approval, and commercialization for gene modified immune cell therapies. Now, we look at what will be needed to take our ability to design immunity from generation 1.0 to 2.0.
- Address the advantages, disadvantages, and unknowns of various gene editing approaches
- Bring new technologies for gene modification and immune cell engineering to the clinic
- Move from concept to scalable product that can achieve regulatory approval and benefit patients